Red Blood Cells Segment, by Wound Type to Account Larger Share in Donor Blood Component Market during 2025-2031

According to our new research study on "Donor Blood Component Market Forecast to 2031 - Global Analysis - by Blood Component, Indication, Application, Age Group, End User, and Geography," the market was valued at US$ 10.08 billion in 2024 and is projected to reach US$ 14.64 billion by 2031; it is expected to register a CAGR of 5.7% during 2025-2031. Rising prevalence of cancer and immunosuppressive diseases and increasing donor awareness are contributing to the growing Donor Blood Component market size. However, the inconsistent voluntary donations hamper the Donor Blood Component market growth. Further, rising demand for plasma-derived therapies are expected to bring in new Donor Blood Component market trends in the coming years.

Donor Blood Component Market Analysis

The donor blood components market is one of the prominent segments of the healthcare industry, driven by the increasing need for safe transfusions during surgery, trauma, cancer treatment, and chronic disease. Donor blood components include red blood cells (RBCs), plasma, platelets, and cryoprecipitate. The donor blood components market growth is being propelled by rising global awareness, aging populations, and growing advancements in collection and storage technologies. However, issues such as low rates of voluntary donations in certain regions, regulatory issues, and logistical limitations remain. New technologies such as apheresis and pathogen reduction systems are improving product safety and efficiency. Furthermore, government and NGO initiatives to increase regular, voluntary blood donation are increasing the donor base. The market has great potential, particularly in evolving healthcare systems.

Donor Blood Component Market Report Scope

The Donor Blood Component market analysis has been carried out by considering the following segments: blood component, indication, application, age group, end user, and geography.

Based on blood component, the donor blood components market is segmented into red blood cells, white blood cells, platelets, plasma, and others. The red blood cells segment held the largest share of the market in 2024. Packed red blood cells (RBCs) are vital for treating anemia, trauma, and chronic conditions. According to an article published in July 2023, The Lancet: New study reveals global anemia cases remain high among women and children, ~1.92 billion people worldwide had anemia in 2021, representing an increase of 420 million cases over three decades. Additionally, according to the American National Red Cross facts, ~29,000 units of RBCs are needed every day in the US and is driven by RBCs need in trauma, surgeries, chronic medical conditions, and cancer care. RBCs are highly utilized in treating anemia and blood loss from surgeries and widespread medical procedures, ranging from trauma care and elective surgeries (cardiac bypass) to chronic disease treatments, such as cancer chemotherapy, and hematological disorders.

By indication, the donor blood components market is bifurcated into immunosuppression and oncology. The immunosuppression segment dominated the market in 2024. The demand for blood-derived products is increasing to treat autoimmune diseases, prevent transplant rejection, and manage immunodeficiency disorders. Immunosuppressive therapies often rely on immunoglobulins, plasma derivatives, and specialized blood components to modulate the immune system. Key indications include organ transplantation, autoimmune diseases, and primary immunodeficiency disorders.

In organ transplantation, immunosuppressive therapies are critical to prevent graft rejection. For instance, intravenous immunoglobulin (IVIG) is used alongside immunosuppressants to reduce rejection risks in kidney, liver, and heart transplants. As per the Global Observatory on Donation and Transplantation (GODT), over 150,000 organ transplants are performed globally each year, with kidney transplants being the most common. The rising prevalence of end-stage renal disease and liver cirrhosis fuels demand for these therapies.

Autoimmune diseases, affecting 5-10% of the global population, also drive market growth. According to the American Autoimmune Related Diseases Association (AARDA), conditions such as rheumatoid arthritis, affecting ~1% of the global population, and systemic lupus erythematosus, with a prevalence of 20-150 per 100,000 people, often require IVIG or plasma exchange to manage severe flares. Chronic inflammatory demyelinating polyneuropathy is another key indication, with IVIG being a first-line therapy. Although rare, PID affects 1 in 1,200 to 2,000 live births, per the Immune Deficiency Foundation data, and necessitates lifelong immunoglobulin replacement therapy. Rising transplant procedures, autoimmune disease incidence, and advancements in blood-based therapies favor the growth of the segment.

Based on application, the donor blood components market is segmented into anemia management, thrombocytopenia treatment, coagulopathy correction, supportive care during chemotherapy, surgery, and others. The anemia management segment held the largest share of the market in 2024. Anemia is a significant public health concern, mainly impacting young children, pregnant and postpartum women, and menstruating adolescent girls and women. According to the World Health Organization (WHO) data, ~30.7% of women aged 15-49 suffered from anemia in 2023. Low- and lower-middle-income countries bear the most significant burden of anemia, mainly affecting populations living in rural settings, in poorer families, with no formal education.

Anemia affects ~25% of the global population and is managed primarily through red blood cell (RBC) transfusions to boost hemoglobin and oxygen delivery. Platelets and plasma are also used in specific cases. Donor blood components play a vital role in treating chronic anemia and severe blood loss. Donor blood components, specifically RBCs, are crucial in managing anemia by replenishing oxygen-carrying capacity. Transfusions help in saving life in extreme anemia, mainly when the body cannot produce enough RBCs or notable blood loss. RBCs are transfused to increase hemoglobin levels and enhance tissue oxygen delivery.

By age group, the donor blood components market is bifurcated into adult and child. The adult segment dominated the market in 2024. The adult population, typically categorized into young adults (18-35 years), middle-aged adults (36-55 years), and older adults (56 years and above). Blood components such as RBCs, platelets, and plasma are vital for treating adults across age groups. The demand for blood components increases with age due to the rising prevalence of chronic diseases and age-related conditions. Young adults support donor pools and trauma care, while middle-aged and older adults need more transfusions due to chronic diseases such as anemia and cancer. According to the American Society of Hematology, anemia is a common blood disorder. It affects over 3 million Americans as well, with ~10% of the adults over 65 being currently anemic. Additionally, platelet donations from young adults are critical for patients undergoing chemotherapy, as platelet counts often drop during cancer treatments. Middle-aged adults increasingly require blood components due to the onset of chronic diseases such as cardiovascular disorders and cancer. Older adults require transfusions due to the increased prevalence of age-associated conditions such as anemia and cancer. Furthermore, hematologic malignancies common in older adults necessitate regular transfusions to manage symptoms and treatment side effects.

As per end user, the donor blood components market is categorized into hospitals, oncology centers, transplant centers, ambulatory surgical centers, and others. The hospitals segment dominated the market in 2024. Donor blood components are essential for treating different medical conditions in hospitals. These components are separated from whole blood and transfused individually based on a patient's needs, allowing one donation to benefit multiple individuals. Hospitals have blood banks or transfusion services that manage blood components' collection, storage, and distribution. They guarantee that blood is appropriately tested for infectious diseases and ABO/Rh compatibility before transfusion. Hospitals also have transfusion committees that implement policies and guidelines for the safe and appropriate use of blood and blood products.

Hospitals rely on donated blood components to treat various medical conditions. Blood donation is separated into multiple components, including platelets, RBCs, and plasma, each performing a specific objective in patient care. These parts are essential for patients undergoing surgery, cancer treatment, and managing various diseases.

Roswell Park Comprehensive Cancer Center, Policlinico of Milan, Vitalant, MD Anderson Cancer Center, The Johns Hopkins Hospital, The Royal Marsden, Gustave Roussy, Peter MacCallum Cancer Centre, Tata Memorial Hospital, Memorial Sloan Kettering Cancer Center are among the leading companies operating in the global Donor Blood Component market.

Companies operating in the Donor Blood Component market adopt various organic and inorganic strategies. Organic strategies mainly include product launches and product approvals. Acquisitions, collaborations, and partnerships are among the inorganic growth strategies witnessed in the Donor Blood Component market. These growth strategies allow the market players to expand their businesses and enhance their geographic presence, thereby contributing to the overall Donor Blood Component market growth. Further, acquisition and partnership strategies help them strengthen their customer base and expand their product portfolios.

Contact Us
Phone: +1-646-491-9876
Email Id: sales@premiummarketinsights.com